IndustryCompany release

Arbutus posts Q3 profit, files new Pfizer/BioNTech suits, and sees FDA lift AB-101 hold

🇺🇸 Arbutus Biopharma Corp (ABUS) · Tue 10 Nov 2026

Arbutus reported $59.1M net income for Q3 2026, as it and Genevant widened LNP patent litigation in Japan and Canada and the FDA cleared its oral PD-L1 candidate.

Arbutus Biopharma reported third-quarter 2026 results on 10 November, showing net income of $59.1M. The company ended the period with $337.5M in cash and securities.

In October, Arbutus returned capital to shareholders through a $230M tender offer. The summary of the results does not detail the source of the quarter's profit beyond the headline's reference to a Moderna payout.

On the litigation front, Arbutus and its partner Genevant filed new suits at the Tokyo District Court and amended an existing Canadian action against Pfizer and BioNTech. The cases concern lipid nanoparticle (LNP) patents relating to the companies' mRNA COVID-19 vaccines.

Separately, the US Food and Drug Administration lifted the clinical hold on the investigational new drug application for AB-101, an oral PD-L1 inhibitor, in October. A Federal Circuit decision on the Moderna appeal under 28 U.S.C. §1498 is still pending.

What it means for your team

  • Teams tracking mRNA vaccine supply should note that LNP patent disputes involving Pfizer/BioNTech now span Japan and Canada, as well as existing proceedings.
  • The lifting of the AB-101 clinical hold allows the oral PD-L1 inhibitor programme to proceed under its IND; a clinical hold is an FDA order to pause or prevent clinical trial activity.
  • The pending Federal Circuit ruling on the Moderna §1498 appeal remains a key event for IP and market-access watchers.

Company's press release (SEC filing): Arbutus Biopharma Corp ↗

Article written by VigiEye from the official source (Arbutus Biopharma Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →